相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Temozolomide-induced inhibition of pituitary adenoma cells Laboratory investigation
Jason Sheehan et al.
JOURNAL OF NEUROSURGERY (2011)
Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells
Ami Sabharwal et al.
MELANOMA RESEARCH (2011)
Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)
Alberto Fernandez et al.
CLINICAL ENDOCRINOLOGY (2010)
MGMT Immunoexpression in Silent Subtype 3 Pituitary Adenomas: Possible Therapeutic Implications
Michael E. Fealey et al.
ENDOCRINE PATHOLOGY (2010)
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases
Marco Losa et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
Zachary M. Bush et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
Gerald Raverot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
O-Methylguanine-DNA Methyltransferase Immunoexpression in a Double Pituitary Adenoma
Safraz Mohammed et al.
NEUROSURGERY (2010)
MGMT immunoexpression in aggressive pituitary adenoma and carcinoma
Queenie Lau et al.
PITUITARY (2010)
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Overlap due to Oral Temozolomide and Cranial Radiotherapy
Nilendu Sarma
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2009)
O6-Methylguanine DNA Methyltransferase Immunoexpression in Nonfunctioning Pituitary Adenomas Are Progressive Tumors Potential Candidates for Temozolomide Treatment?
Georg Widhalm et al.
CANCER (2009)
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Santosh Kesari et al.
CLINICAL CANCER RESEARCH (2009)
被撤回的出版物: Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma (Retracted Article. See vol 15, pg 3240, 2009)
Christina K. Augustine et al.
CLINICAL CANCER RESEARCH (2009)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
Ann I. McCormack et al.
CLINICAL ENDOCRINOLOGY (2009)
High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease
Akira Takeshita et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Treatment of Nelson's syndrome with temozolomide
V. J. Moyes et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
C. Hagen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Hypersensitivity pneumonitis associated with temozolomide
L. Guilleminault et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma
Luis V. Syro et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2009)
Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas?
Mustafa Khasraw et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Jennifer A. Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
New (alternative) temozolomide regimens for the treatment of glioma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2009)
USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS: CASE REPORT
Safraz Mohammed et al.
NEUROSURGERY (2009)
Management of aggressive pituitary adenomas: current treatment strategies
Michael Buchfelder
PITUITARY (2009)
A Rare Case of Aplastic Anemia Caused by Temozolomide
Benjamin J. George et al.
SOUTHERN MEDICAL JOURNAL (2009)
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide
Bart Neyns et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of extended-dose temozolomide in patients with melanoma
Petra Rietschel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
Kalman Kovacs et al.
ACTA NEUROPATHOLOGICA (2008)
Triazene compounds: Mechanism of action and related DNA repair systems
Francesco Marchesia et al.
PHARMACOLOGICAL RESEARCH (2007)
A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors
Anne Wierinckx et al.
ENDOCRINE-RELATED CANCER (2007)
MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents
Bernd Kaina et al.
DNA REPAIR (2007)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P. Cahill et al.
CLINICAL CANCER RESEARCH (2007)
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
Lisa M. Neff et al.
PITUITARY (2007)
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
P. Hau et al.
NEUROLOGY (2007)
Pathohistological classification of pituitary tumors:: 10 years of experience with the German Pituitary Tumor Registry
Wolfgang Saeger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings
Kalman Kovacs et al.
HUMAN PATHOLOGY (2007)
High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium
Adrian F. Daly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm
Luis V. Syro et al.
CLINICAL ENDOCRINOLOGY (2006)
Long-term response of pituitary carcinoma to temozolomide - Report of two cases
Camilo E. Fadul et al.
JOURNAL OF NEUROSURGERY (2006)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
MH Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Targeted modulation of MGMT: Clinical implications
LL Liu et al.
CLINICAL CANCER RESEARCH (2006)
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas
M Brell et al.
CLINICAL CANCER RESEARCH (2005)
Clinical review: Diagnosis and management of pituitary carcinomas
GA Kaltsas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island
W Zhao et al.
JOURNAL OF BIOCHEMISTRY (2005)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
M Möllemann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Inhibition of angiogenesis by non-toxic doses of temozolomide
H Kurzen et al.
ANTI-CANCER DRUGS (2003)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
